跳至主要内容
临床试验/NCT01240551
NCT01240551已完成2 期

A Pilot Study of F-18 Sodium Fluoride PET/CT for Metastatic Burden Qualification in Prostate Cancer

National Cancer Institute (NCI)1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2010年11月30日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
60
试验地点
1
主要终点
Number of Participants With Present or Not Present Bone Metastasis

研究概览

简要总结

Background:

  • Sodium fluoride (NaF) is a common compound that is found in various foods and can be used to increase bone strength. When this compound is added to a small dose of radiation (F-18), it collects in the bones, with higher amounts in areas where the bone is rapidly changing, such as the site of a healing fracture or a tumor. By giving F-18 NaF before a combined positron emission tomography/ computed tomography (PET/CT) scan, researchers hope to be able to better measure the changes in the bone that may indicate that a certain type of cancer (such as prostate cancer) has spread to the bones.

Objectives:

  • To evaluate the effectiveness of F-18 NaF in imaging studies to measure bone tumors and their change over time and compare with clinical course, in individuals with prostate cancer.
  • To determine the smallest amount of change in the bone tumors that F-18 NaF can accurately measure.

Eligibility:

  • Men at least 18 years of age who have been diagnosed with prostate cancer and have had imaging studies to determine whether the cancer has spread to their bones. Both patients with and without known bone involvement will be enrolled.

Design:

  • Participants will be screened with a physical examination, medical history, and imaging studies, and will provide baseline blood samples to evaluate kidney function.
  • For the study, participants will have two F-18 NaF PET/CT scans on separate days for baseline. These repeat scans will be used to determine the amount of change that is due to the imaging process alone (i.e. not due to the disease getting better or worse. Participants will receive a dose of F-18 NaF intravenously, and will have PET/CT scanning over the body (mid ear to upper thighs) over 1 hour, the body followed by a complete whole-body PET/CT scan at approximately 2 hours after F-18 NaF injection. Participants will be watched closely for side effects from the F-18 NaF until the scans are done, and will be asked to drink plenty of water to void the F-18 NaF from the body after the scans.
  • As a followup study, participants will have two more F-18 NaF PET/CT scans, one 4 to 8 months after the first scans and then one 10 to 14 months after the first scans. Participants will provide additional blood samples before the followup scans.

详细描述

Background:

  • Evaluating response to therapy in prostate cancer is limited by the inability to quantify bony metastatic disease
  • F-18 sodium fluoride (NaF) is a PET radiopharmaceutical which localizes in regions of bony turnover, and was the 1st bone scan agents (prior to Tc-99m MDP (methylene diphosphonate) availability)
  • Today s high sensitivity PET cameras can image the distribution of F-18 NaF as a whole body volume and permit quantification of uptake over time. The addition of co-registered CT increases the diagnostic accuracy for detection of metastatic disease

Primary Objective:

-To evaluate the feasibility of using NaF PET/CT to quantitatively measure the extent of bony metastatic disease in patients with prostate cancer in patients

  • To determine the intra-patient reproducibility of F-18 NaF PET/CT
  • To explore the relationship between the biodistribution changes in F-18 NaF PET/CT parameters and the clinical response

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

Mets via NaF-18 PET/CT

Active Comparator

Patients with known bone metastases (i.e. mets).

干预措施: F-18 NaF (Drug)

No-Mets via NaF-18 PET/CT

Active Comparator

Patients with no clinical evidence of bone metastases

干预措施: F-18 NaF (Drug)

结局指标

主要结局

Number of Participants With Present or Not Present Bone Metastasis

时间窗: Single imaging sessions will be acquired at baseline, between 4-6 months and between 10-12 months on emolument.

Present and not present bone metastasis was determined by sodium fluoride (NaF) PET (positron emission imaging)/CT (computed tomography) imaging. Present bone metastasis is defined as greater than normal bone uptake. Not present bone metastasis is defined as physiological bone uptake of F-18 NaF on PET/CT imaging (i.e. excluding traumatic and degenerative foci of increased F-18 NaF uptake.

次要结局

  • Number of Participants With Adverse Events(date treatment consent signed to date off study, approximately 52.5 months)

研究者

申办方类型
Nih
责任方
Principal Investigator
主要研究者

Karen Kurdziel, M.D.

Principal Investigator

National Institutes of Health Clinical Center (CC)

研究点 (1)

Loading locations...

相似试验